



Innovating Technologies for Life

ITL Limited
ABN 16 088 212 088

PO Box 139
Fyshwick Canberra
ACT 2609 Australia

Tel +61 2 6280 8535
Fax +61 2 6280 8538

www.itl-limited.com

Monday, 21 August 2006

ITL signs 5 year supply deal with bioMérieux.

ITL is pleased to announce a five year supply agreement with bioMérieux for ITL's new SampLok[®] Blood Collection Adapter for use with the BacT/ALERT[®] product line.

bioMérieux, a leader in the field of *in vitro* diagnostics and bacterial detection testing, will purchase the safety devices for further distribution to clinical end users.

bioMérieux is a long-standing industry leader and innovator within the *in vitro* diagnostics industry. Their products include test instruments, reagents, software and other ancillary devices. bioMérieux is also a leader in driving safety in the workplace with its market-exclusive plastic BacT/ALERT blood culture bottles.

“We’re delighted to be selected by bioMérieux to supply our new SampLok[®] Blood Collection Adapter safety product line to the global hospital market. It’s a significant step by bioMérieux towards continued global needle safety awareness and we are very pleased to be part of the evolution of safety in the healthcare workplace ” said Bill Mobbs, ITL’s CEO.

The new SampLok[®] Blood Collection Adapter is an important platform for ITL's bacterial detection safety ancillary product line and supplements our SSK[®] product offerings.

This new product line directly supports bioMérieux’ commitment to enhancing the safety of healthcare workers worldwide.

ITL continues to be a leader in design and development of safety devices to address the critical issue of needlestick injuries in the global healthcare industry.

About ITL’s Innovative Products

Safety, Ergonomics and Best Practice

ITL’s award winning needle guards and integrated safety systems for both the blood and renal care markets are used extensively in blood collection centers and hospitals for patients requiring blood tests, blood transfusions, or haemodialysis procedures. Visit www.itl-limited.com

(More over page)

About bioMérieux

bioMérieux is a leading international diagnostics group that specializes in the field of in vitro diagnostics for clinical and industrial applications. bioMérieux designs, develops, manufactures and markets systems (i.e. reagents, instruments and software) used in:

Clinical applications: the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancer, based on the analysis of biological samples (such as blood, saliva or urine); and

Industrial applications: the microbiological analysis of food, environments (such as water and air), surfaces and pharmaceutical and cosmetic products, based on the analysis of product or environmental samples.

In 2005, bioMérieux sales reached 994 million euros. The company is present in more than 130 countries through 35 subsidiaries and a large network of distributors, which positions the company well to benefit from the growth potential of the in vitro diagnostics market. Some important drivers that underpin this growth are aging populations and age-related illness, illnesses related to life-style and eating habits, emerging new pathogens, the development of antibiotic-resistant bacteria, the fight against bio-terrorism, and the recognition of the importance of the quality of food products. bioMérieux is listed on the Eurolist of Euronext, Paris (FR0010096479 – BIM). Other information can be found at www.biomerieux.com

For more information:

Bill Mobbs
CEO

ITL (ASX: ITD, www.itl-limited.com) designs and manufactures innovative medical devices and procedure packs for global healthcare markets. ITL is committed to bringing products to the market that consistently prove to be market leaders in safety and innovation and supplies 200 private and public hospitals across Australia with its range of customised Procedure Packs. ITL's products have a presence in over 35 countries and protect the lives and health of healthcare workers in millions of procedures annually.